Proteomics-based insights into mitogen-activated protein kinase inhibitor resistance of cerebral melanoma metastases

Proteomics-based insights into mitogen-activated protein kinase inhibitor resistance of cerebral melanoma metastases

Abstract Background MAP kinase inhibitor (MAPKi) therapy for BRAF mutated melanoma is characterized by high response rates but development of drug resistance within a median progression-free survival (PFS) of 9–12 months. Understanding mechanisms of resistance and identifying effective therapeutic a...

Full description

Bibliographic Details
Main Authors: Nina Zila, Andrea Bileck, Besnik Muqaku, Lukas Janker, Ossia M. Eichhoff, Phil F. Cheng, Reinhard Dummer, Mitchell P. Levesque, Christopher Gerner, Verena Paulitschke
Format: Article
Language:English
Published: BMC 2018-03-01
Series:Clinical Proteomics
Subjects:
BRAF mutation
Cerebral melanoma metastases
Drug resistance
Melanoma
MAP kinase inhibitor
Proteomics
Online Access:http://link.springer.com/article/10.1186/s12014-018-9189-x

Internet

http://link.springer.com/article/10.1186/s12014-018-9189-x

Similar Items